ESH MM 2018 | PVX-410 vaccine for smoldering myeloma
Noopur Raje
• 5 Oct 2018
Vaccines are an exciting prospect for multiple myeloma (MM), and here Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, tells us about the multi-peptide PVX-410 vaccine trial for smoldering MM (NCT01718899), for which she is a principal investigator. This exciting strategy aims to prevent progression to MM. Dr Raje discusses the four targets of the vaccine and the results observed in terms of immunogenicity, and highlights the next step of investigation with the addition of a HDAC inhibitor. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
